This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
by Zacks Equity Research
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
Lilly (LLY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly (LLY) Q1 Earnings Lag Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -6.36% and 2.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings
by Mark Vickery
Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.
Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More
by Ahan Chakraborty
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Why Earnings Season Could Be Great for Eli Lilly (LLY)
by Zacks Equity Research
Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly (LLY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Sanofi (SNY) Surpass Estimates This Earnings Season?
by Zacks Equity Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $370.47 in the latest trading session, marking a +0.15% move from the prior day.
Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway
by Zacks Equity Research
Eli Lilly, Thermo Fisher Scientific, Lockheed Martin, Boston Scientific and Canadian Pacific Railway are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Thermo Fisher Scientific & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO) and Lockheed Martin Corporation (LMT).
Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA
by Zacks Equity Research
The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.
J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View
by Kinjel Shah
FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $375.15, marking a +1.65% move from the previous day.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
Alexandria (ARE) Transfers Partial Interest in 15 Necco Street
by Zacks Equity Research
Amid the solid demand for high-quality life science assets, Alexandria (ARE) closes the strategic partial interest transaction for 15 Necco Street to a U.S. affiliate of Mori Trust Co., Ltd.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
3 Sector ETFs to Play as Recession Fears Are on the Rise
by Yashwardhan Jain
With recession fears on the rise, look into some sectors that can shield from market volatility.